The firm is present in personal care, pharma, baby care, animal health and wellness segments.
"In the pharma business, we are looking to be present in 200-plus outlets, from 160 currently, and aim to cover over 1.5 lakh doctors this year," he added.
The company is also looking to double its sales force in baby care from 800 to over 1,500 personnel.
The Bengaluru-headquartered company recently set up a new division to focus on non-prescription drugs in areas like immunity, joint care, women's health and vitality. It expects Rs 100 crore revenue from this division in the current fiscal.
"We started the (wellness) division in December and are well within reach of our target to earn Rs 100 crore in turnover this year from wellness," Haydon said.
The wellness market in the country is estimated at Rs 14,000-crore and is currently dominated by two categories -- cough and cold medicines and health drinks.
Personal care has also evolved into a key business category for the company, with the segment contributing to over 40% of the company's Rs 2,000 crore turnover, followed by pharmaceuticals (35%), baby care (13%) and animal health and wellness.
The company plans to use its existing network of doctors, chemists and pharmacies to promote its wellness range, besides being present in supermarkets and small retail outlets.
According to Haydon, the company hopes to grow at a compound annual rate of 20-25% till 2020.
Personal care is growing at around 30% while baby care segment growth stands at around 50%.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.